Evidence map›Paper›PMID 28378193›Full record

ArticlePharmacoEconomics2017

Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.

Daisuke Goto, Ya-Chen Tina Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze, Yujin Park, C Daniel Mullins

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daisuke GotoDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, 220 Arch St., 12th floor, Baltimore, MD, 21201, USA. dgoto@rx.umaryland.edu.ORCID http://orcid.org/0000-0003-4921-3851
Ya-Chen Tina ShihDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Pascal LecomteNovartis AG, Lichtstrasse 35, 4056, Basel, Basel-Stadt, Switzerland.
Melvin OlsonNovartis AG, Lichtstrasse 35, 4056, Basel, Basel-Stadt, Switzerland.
Chukwukadibia UdezeDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, 220 Arch St., 12th floor, Baltimore, MD, 21201, USA.
Yujin ParkNovartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
C Daniel MullinsDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, 220 Arch St., 12th floor, Baltimore, MD, 21201, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving comprehensive patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics. Increased availability and accessibility of patient-level health-related utility data from clinical trials or observational database provide enhanced opportunities to conduct more patient-centered CEA. Regression-based approaches that incorporate patient-level data hold great promise for enhancing CEAs to be more patient centered; this paper provides guidance regarding two CEA approaches that apply regression-based approaches utilizing patient-level health-related utility and costs data. The first approach utilizes patient-reported preferences to determine patient-specific utility. This approach evaluates how individuals' unique clinical and demographic factors affect their utility and cost levels over the course of treatment. The underlying motivation of this approach is to produce CEA estimates that reflect patient-level utilities and costs while adjusting for socio-demographic and clinical factors to aid patient-centered coverage and treatment decision-making. In the second approach, patient utilities are estimated based on the clinically defined health states through which a patient may transition throughout the course of treatment. While this approach is grounded on the widely used Markov transition model, we refine the model to facilitate an enhancement in conducting regression-based analysis to achieve transparent understanding of differences in utilities and costs across diverse patient populations. We discuss the unique statistical challenges of each approach and describe how these analytical strategies are related to non-regression-based models in health services research.

Indexed as

Cost-Benefit AnalysisHealth StatusHumansRegression Analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.